-
Mashup Score: 2Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma - 1 year(s) ago
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, shares some updates from the POLLUX trial (NCT02076009), which is comparing the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In this video, Yasmin Nouri, BSc, MSc, Malaghan Institute of Medical Research, Wellington, New Zealand, shares some insights into the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yasmin Nouri (@Malaghan_Inst) spoke with us at #CART23 on novel third-generation TLR2 co-stimulatory CAR-T cells being explored for B-cell malignancies: 👉https://t.co/mXvSIEWorI👈 @TheEBMT @EHA_Hematology #CARTcell #ImmunoOnc
-
-
Mashup Score: 1Management strategies for early and late infections in patients undergoing CAR-T cell therapy - 1 year(s) ago
Andriyana Bankova, MD, University Hospital Zurich, Zurich, Switzerland, gives an overview of management strategies for early and late infections following…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about current management strategies for early and late infections following CAR-T therapy in our interview with Andriyana Bankova (@UZH_en): 🎥: https://t.co/EvLwLrR2E4 @TheEBMT @EHA_Hematology #CART23 #HemOnc #ImmunoOnc #CARTcell #tcellrx
-
-
Mashup Score: 0KarMMa-3 trial updates: ide-cel versus SOC in triple-class exposed R/R multiple myeloma - 1 year(s) ago
In this video, Paula RodrÃguez-Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, shares some updated results from the KarMMa-3…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CART23 | Paula RodrÃguez-Otero (@paurotero) shares some updates from the KarMMa-3 trial, which is evaluating ide-cel versus SOC in patients with triple-class exposed R/R myeloma. Watch here: 👉https://t.co/5R32zElFKD👈 #MMsm #MyelomaAwarenessMonth @TheEBMT @EHA_Hematology
-
-
Mashup Score: 1
Michelle Kenyon, King’s College Hospital NHS Foundation Trust, London, UK, discusses the important role that nurses play during a patient’s…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nurses play a valuable role in supporting patients during CAR-T therapy. Find out more in our interview with @michellekenyon5: 🎥: https://t.co/HZhvesvRp2 @TheEBMT @EHA_Hematology #Nursing #CARTcell #HemOnc #ImmunoOnc #tcellrx #CART23
-
-
Mashup Score: 1CAR-T Meeting 2023 | VJHemOnc - 1 year(s) ago
The EBMT-EHA 5th European CAR T-cell Meeting 09–11 February 2023 | Rotterdam, Netherlands / Online Jointly organized by the EBMT and EHA, the 5th European CAR T-cell Meeting took place on February 9-11, 2023, in Rotterdam, The Netherlands, and online, and covered the latest translational, clinical, and…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Missed out on #CART23? Don't worry! We have all you need - watch our exclusive interviews to find out the latest developments in CAR-T therapy from this year's meeting: 👉https://t.co/pc9wpnCWu6👈 @TheEBMT @EHA_Hematology #HemOnc #CARTcell #ImmunoOnc #LymSM #LeuSM #MMsm https://t.co/UQ4AMc55Ta
-
-
Mashup Score: 0
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses challenges with developing efficacious CAR-T cell products for…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sascha Haubner (@MSKCancerCenter) discusses challenges with implementing CAR-T therapy in AML & shares some insights into novel IF-BETTER-gated CAR-T cells. Watch his interview here: 🎥: https://t.co/xhVdj9BtSm @TheEBMT @EHA_Hematology #AMLsm #LeuSM #CART23 #CARTcell
-
-
Mashup Score: 1CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading? - 1 year(s) ago
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, shares some insights into clinical indications for…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our exclusive interview with John Gribben (@QMBCI), who discusses current and future indications for CAR-T therapy in acute and chronic leukemias: 👉https://t.co/HZUbXA4d8t👈 @TheEBMT @EHA_Hematology #CART23 #HemOnc #LeuSM #AMLsm #ALLsm #CLLsm #CARTcell #ImmunoOnc
-
-
Mashup Score: 0Unmet needs in second-line DLBCL and challenges in this space - 1 year(s) ago
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses unmet needs…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Wendy Osborne (@NewcastleHosps) discusses unmet needs in second-line DLBCL & challenges in this space: 👉https://t.co/lgG7UVhqUv👈 @TheEBMT @EHA_Hematology #CART23 #LymSM #CARTcell #BMTsm #HemOnc #ImmunoOnc #DLBCL
-
-
Mashup Score: 1
In this video, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into the role of CAR-T…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about clinical indications for CAR-T therapy in mantle cell lymphoma & follicular lymphoma in our exclusive interview with Ulrich Jäger (@MedUni_Wien): 👉https://t.co/YEMOnh1bZy👈 @TheEBMT @EHA_Hematology #CART23 #LymSM #HemOnc #ImmunoOnc #CARTcell
-
Philippe Moreau (@CHUnantes) shares updated overall survival data from the POLLUX trial. Watch his interview here: 👉https://t.co/eqf2jwdrGi👈 @TheEBMT @EHA_Hematology #CART23 #MMsm #HemOnc #ImmunoOnc